MOL THER-ONCOLYTICS 润色咨询

Molecular Therapy-Oncolytics

出版年份:暂无数据 年文章数:151 投稿命中率:22.0%

出版周期:暂无数据 自引率:3.3% 审稿周期:平均3月

前往期刊查询

投稿信息

投稿信息
审稿速度
平均3月 (网友贡献,非官方数据)
投稿命中率
22.0% (网友贡献,非官方数据)
审稿费用
3500.0元/篇 (网友贡献,非官方数据)
版面费用
3500.0元/篇 (网友贡献,非官方数据)
中国人发表比例
2019年中国人文章占该期刊总数量40.23% (2018年为13.79%)
自引率
3.3 %
年文章数
151
期刊官网
点击查看 (点击次数:2843)
点击查看 (点击次数:1686次)
作者需知
点击查看 (点击次数:264次)
期刊简介
稿件收录要求

Molecular Therapy

Molecular Therapy is the leading journal for research in the areas of gene transfer, vector development and design, stem cell manipulation, development of gene-, peptide-, protein-, oligonucleotide-, and cell-based therapeutics to correct genetic and acquired diseases, vaccine development, pre-clinical target validation, safety/efficacy studies, and clinical trials. Molecular Therapy is dedicated to promoting the sciences in genetics, medicine, and biotechnology. Publishing important peer-reviewed research and cutting-edge reviews and commentaries, the journal continues to attract the best material in the field. Molecular Therapy''s 2015 impact factor is 6.938.

Molecular Therapy — Oncolytics

Molecular Therapy—Oncolytics is an international, online-only, open-access journal focusing on the development and clinical testing of viral, cellular, and other biological therapies targeting cancer. While providing a unique forum for work in the burgeoning fields of oncolytic virotherapy, as well as T cell- and stem cell-based therapies, the journal will consider all top-quality, cutting-edge research that employs innovative molecular and cellular approaches that target cancer cells for destruction, whether by viruses,  other microorganisms, vaccination, or transfer of cells and/or genes. As an official journal of the American Society of Gene & Cell Therapy, Molecular Therapy—Oncolytics will build upon the success of Molecular Therapy and its sibling journals in publishing important peer-reviewed original research and editorial commentary.